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Abstract
There is an urgent need for better drugs for a more successful fight against leishmaniasis,
one of the most important neglected diseases caused by the parasite Leishmania. We have
recently synthesized several symmetrical pyridinium compounds belonging to two dif‐
ferent series: bis-pyridinium and bis-quinolinium acyclic structures and bis-pyridinium
diazacyclophanes derivatives. The first series of bis-pyridinium derivatives have been
found to display activity against promastigotes and intracellular amastigotes of Leishma‐
nia donovani and Leishmania major, with EC50 values lower than 1 μM. The majority of
compounds show a similar behavior in both Leishmania species, being slightly more active
against intracellular amastigotes of L. major. The series of bis-pyridinium diazacyclo‐
phanes can be considered as rigid analogues of the previous bis-cationic ones. The activi‐
ty of these compounds has also been evaluated against promastigotes and intracellular
amastigotes of L. donovani and L. major. All the diazacyclophanes are more active against
L. major, with EC50 values of between 1 and 17 μM in intracellular amastigotes, and in
some cases they present a higher selectivity index than the reference anti-leishmanial
drugs such as amphotericin B and miltefosine. In conclusion, these bis-quaternary com‐
pounds represent promising candidates as potential therapeutic agents against leishma‐
niasis.
Keywords: Pyridinium phanes, diazacyclophanes, leishmaniasis, Leishmania chemothera‐
py
1. Introduction
Leishmaniasis is a major group of neglected tropical diseases caused by the protozoan parasite
Leishmania. Currently it affects 12 million people in 98 countries, and around 350 million people
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worldwide are at risk of infection [1]. Leishmaniasis is responsible for a variety of pathologies
that have been classified in three main clinical manifestations including cutaneous (CL),
mucocutaneous (MCL), and visceral (VL) leishmaniasis, ranging from self-healing cutaneous
lesions to fatal visceral infection [2].
All Leishmania species are digenetic parasites that exist as both insect vector (promastigotes)
and mammalian forms (intracellular amastigotes). The digenetic life cycle of Leishmania
consists of flagellated, motile, extracellular promastigote form that proliferates in the midgut
of phlebotomine sand fly family vectors, which infect mammalian host and transform into the
non-motile, intracellular amastigote form that resides in phagolysosomes of macrophages and
other reticuloendothelial cells.
Since an effective vaccine against leishmaniasis is not available, chemotherapy is at present
the only effective way to treat all forms of the disease. The recommended first-line therapies
for leishmaniasis include pentavalent antimonials such as sodium stibogluconate and meglu‐
mine antimoniate, amphotericin B (AmB), paromomycin, and miltefosine (Figure 1), all of
which have different types of limitations including toxicity, price, efficacy, and emerging
resistance [3], which emphasizes the importance of developing new drugs against leishma‐
niasis. Pentamidine [1,5-bis(4-amidinophenoxy)pentane] is an aromatic diamidine (Figure 1)
widely used for the treatment of sleeping sickness caused by Trypanosoma brucei [4]. It was
used as a second-line drug against VL in cases of antimony failure, but its use against leish‐
maniasis is now limited to the treatment of some forms of CL in South America [5]. Pentami‐
dine acts at the mitochondrial level of the parasite by accumulating within the mitochondria
and binding to DNA, thus interfering with the replication and transcription [6]. Novel
diamidine derivatives with improved pharmacokinetic properties have been under develop‐
ment in recent years [7, 8].
New diamidine and choline-derivative dications have been developed recently in order to find
new drugs with improved activity against leishmaniasis and lower toxicity [9–12] (Figure 2).
Chemistry is a science on which all the other sciences are based. An understanding of biology
requires knowledge of chemistry. The majority of the leishmaniasis reviews are concentrating
on the biology of the processes and very little on the chemistry. We would like to fill this gap
and we will focus on the chemical structures that could be useful to the medicinal chemists
working in this important area of research.
Here we present the anti-leishmanial activity of a set of symmetrical bis-pyridinium com‐
pounds with cyclic or acyclic structures. Both types of compounds can be named according to
the IUPAC nomenclature for phanes, a method based on assembling names that describe
component parts of a complex structure.
2. Symmetrical bis-pyridinium compounds
We have previously designed and synthesized a set of symmetrical bis-pyridinium com‐
pounds, which consist of a linker and two cationic heads which are 4-substituted pyridinium
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or quinolinium rings with cyclic or acyclic amino groups, as inhibitors of the human choline
kinase (ChoK) (Table 1), the first enzyme in the CDP–choline pathway that synthesizes
phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. In humans,
choline kinase exists as three isoforms (ChoKα1, α2, and β). Specific inhibition of ChoKα has
been reported to selectively kill the tumor cells. Ten symmetrical bis-pyridinium and bis-
quinolinium derivatives were tested for their ability to inhibit human ChoKα2, and VGP-118
and VGP-150 were identified as highly potent choline kinase inhibitors with EC50 values of 80
nM. Kinetic enzymatic assays indicated a mixed, predominantly competitive, inhibition
mechanism for these compounds. These novel compounds showed strong anti-proliferative
activity (EC50 of 1 μM) on the human breast cancer SKBR3 cell line [13].
In addition, these compounds can be considered as structural analogues of pentamidine in
which the amidino moiety, which is protonated at physiological pH, has been replaced by a
positively charged nitrogen atom as a pyridinium ring. In view of this structural resemblance
and with the intention of identifying potential drugs against leishmaniasis, we analyzed the
anti-leishmanial activity of these bis-pyridinium derivatives.
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Figure 1. Anti-leishmanial drugs.
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2.1. Susceptibility analysis in Leishmania lines
The anti-leishmanial activity of the ten choline kinase inhibitors was evaluated against
promastigotes and intracellular amastigotes of Leishmania donovani and Leishmania major in
order to identify the potential hits for further optimization. The cytotoxic effect of these
compounds was also investigated on the human monocytic cell line THP-1, the host cell used
in the assay with intracellular amastigotes. Selectivity indexes (SI) were calculated as the ratio
of the EC50 (the concentration of compound required to inhibit growth by 50%) for THP-1 to
the EC50 for intracellular amastigotes. Table 2 shows the results, where miltefosine and AmB
were used as the reference anti-leishmanial drugs. Most assayed compounds exhibit a specific
high activity against promastigotes and intracellular amastigotes of L. major, with EC50 values
between 0.09 and 0.42 μM in amastigotes, except for compounds VGP-106 and VGP-118 (EC50
13.07 and 6.21 μM, respectively). With regard to L. donovani, all assayed compounds display
EC50 values below 1 μM in promastigotes, except compound VGP-138 (EC50 2.11 μM).
Although these values are slightly higher in intracellular amastigotes, they are similar to those
for the anti-leishmanial drug miltefosine [14].
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Figure 2. Potent diamidine and charged derivatives with improved activity against leismaniasis.
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Our analysis of the effect on THP-1 cells showed that bis-pyridinium derivatives (VGP-106,
VGP-114, VGP-118, VGP-130, VGP-138) are less cytotoxic than the bis-quinolinium counter‐
parts (VGP-146, VGP-150, VGP-162, VGP-174, VGP-182), with a higher SI than miltefosine
(Table 2).
Het
Linker
Het
Compound Het Linker
VGP-106 N N Br
VGP-114 N N CF3
VGP-118 N N Br (CH2)4
VGP-130 N N CF3
VGP-138 N N
VGP-146
N N
Cl
(CH2)4
VGP-150
N N
Cl
VGP-162
N N
Cl
(CH2)2
VGP-174
N
H
N Cl
VGP-182
N
H
N I
Table 1. Structure of the bis-cationic compounds
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EC50 promastigotes (µM) EC50 amastigotes (µM) [SI]b THP-1 toxicity EC50
(µM)Compound L. major L. donovani L. major L. major
VGP-106 21.55 ± 3.72 0.36 ± 0.09 13.07 ± 6.30 [15.8] 0.86 ± 0.46 [240.2] 206.54 ± 9.89
VGP-114 0.47 ± 0.04 0.61 ± 0.09 0.10 ± 0.03 [1000.6] 0.85 ± 0.04 [117.7] 100.06 ± 8.57
VGP-118 29.15 ± 5.73 0.65 ± 0.19 6.21 ± 1.02 [2.4] 0.18 ± 0.03 [85.3] 15.35 ± 3.99
VGP-130 0.50 ± 0.07 0.73 ± 0.11 0.09 ± 0.02 [903.7] 2.02 ± 0.05 [40.3] 81.34 ± 10.65
VGP-138 0.74 ± 0.19 2.11 ± 0.48 0.30 ± 0.16 [586.8] 4.01 ± 0.43 [43.9] 176.05 ± 20.75
VGP-146 0.21 ± 0.06 0.33 ± 0.07 0.10 ± 0.04 [156.1] 0.42 ± 0.01 [37.2] 15.61 ± 3.26
VGP-150 0.36 ± 0.11 0.77 ± 0.04 0.09 ± 0.03 [267] 0.55 ± 0.16 [43.7] 24.03 ± 5.42
VGP-162 0.40 ± 0.08 0.35 ± 0.02 0.37 ± 0.03 [29.6] 1.00 ± 0.08 [11.0] 10.97 ± 2.41
VGP-174 1.70 ± 0.01 0.34 ± 0.03 0.41 ± 0.05 [6.1] 0.86 ± 0.03 [2.8] 2.47 ± 0.05
VGP-182 2.51 ± 0.01 0.92 ± 0.2 0.42 ± 0.12 [11.2] 0.52 ± 0.12 [9.1] 4.71 ± 0.23
AmB 0.32 ± 0.02 0.21 ± 0.01 0.24 ± 0.01 [59.7] 0.28 ± 0.13 [51.1] 14.32 ± 4.10
Miltefosine 16.65 ± 1.23 6.60 ± 1.57 10.61 ± 0.89 [2.5] 0.88 ± 0.14 [30.5] 26.86 ± 3.08
aParasites were grown for 72 h at 28 °C (promastigotes) or 37 ºC (intracellular amastigotes) in the presence of increasing
concentrations of compounds. THP-1 cells were grown for 72 h at 37 ºC, in the presence of increasing concentrations of
compounds. Promastigotes and THP-1 viability was determined using an MTT-based assay. Number of intracellular
amastigotes was determined by nuclear staining. AmB and miltefosine were used as standard anti-leishmanial agents.
Data are means ± SD of three independent determinations.
bSelectivity indexes [SI] were calculated by dividing the EC50 THP-1 by that for intracellular amastigotes. Compound
VGP-106 (grey color) was selected for further studies of the mechanism of action.
Table 2. Anti-leishmanial activity and toxicity in THP-1 cells of symmetrical bis-pyridinium compounds.a
Compound VGP-106 was identified as a representative compound that displayed a potent
activity against L. donovani intracellular amastigotes. As the least cytotoxic of the set of
compounds assayed for THP-1 cells, it was selected to further elucidate their mechanism of
action in this protozoan parasite [14].
2.2. Drug susceptibility assay of L. donovani lines overexpressing CEK or EK
Considering that the Leishmania genome includes two homologous enzymes of human ChoK,
namely, choline/ethanolamine kinase (CEK) and ethanolamine kinase (EK), we decided to
study whether there is a correlation between their ChoK inhibitory activity and anti-leishma‐
nial activity. These proteins can be overexpressed in L. Donovani promastigotes by transfecting
the parasites with a plasmid encoding the Leishmania CEK (pXG-CEK) or EK (pXG-EK) genes
[14]. The susceptibility of transfected parasites to compound VGP-106 was determined in both
promastigotes and intracellular amastigotes. As can be seen from Table 3, there are no
significant differences between the EC50 values of parasites overexpressing CEK or EK
enzymes compared to control parasites. These results suggest that the mechanism of action of
this compound in Leishmania is independent of the aforementioned enzymes [14]. If this were
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not the case, overexpression of these enzymes would have resulted in an increase in the EC50
value.
EC50 (µM)
Plasmid Promastigotes Amastigotes
pXG 0.36 ± 0.09 0.45 ± 0.03
pXG-CEK 0.36 ± 0.09 0.42 ± 0.05
pXG-EK 0.43 ± 0.05 0.35 ± 0.03
aControl (pXG) and transfected (pXG-CEK and pXG-EK) parasites were grown for 72 h at 28 °C (promastigotes) or 37 ºC
(intracellular amastigotes) in the presence of increasing concentrations of compounds. Data are means ± SD of three
independent determinations.
Table 3. Susceptibility to VGP-106 of L. donovani lines overexpressing CEK or EK.a
3. Symmetrical bis-pyridinium diazacyclophanes
Rigidification is a commonly used strategy to increase the activity of a drug or to reduce its
side effects. A cyclophane is a hydrocarbon consisting of an aromatic unit (typically a benzene
ring) and an aliphatic chain that forms a bridge between two non-adjacent positions of the
aromatic ring.
We have synthesized a new family of symmetrical bis-pyridinium diazacyclophanes designed
as cyclic analogues of previously reported acyclic bis-pyridinium derivatives, by cyclization
through the exocyclic nitrogen atoms at position 4 of the pyridinium moiety via linker 2, which
leads to the diazacyclophane targets (Figure 3) [15]. These compounds have been evaluated
against L. major and L. donavani.
2Br
HN NH
N N
2Br
NRR' NRR'
N N
Linker 1
Cyclization
Linker 2
Linker 1
A B
Figure 3. Structural variation that leads to symmetrical bis-pyridinium diazacyclophanes (B) from symmetrical acyclic
bis-pyridinium derivatives (A).
This new compounds are symmetrical bis-pyridinium derivatives which differ from each other
in the upper and lower spacers. Four different spacers were used: two are phenyl-p-diyl‐
methylene and phenyl-m-diylmethylene linkers, and the other two are aliphatic, such as the
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1,5-pentanediyl and 3-oxa-1,5-pentanediyl moieties. At least one of the two spacers in every
cyclophane is an aliphatic linker (Table 4).
The final compounds were synthesized according to Scheme 1. Dipyridines 1 and 2 were
prepared from commercially available diamines and 4-bromopyridine in the presence of
phenol under argon atmosphere, as previously described [11]. A reaction involving phenol as
proton donor, solvating agent, and source of phenoxide ion is envisaged, as outlined in Scheme
1 [16]. As a reaction medium, phenol reduces both the reaction time and temperature of the
halogen-replacement reactions.
N
O
H
N
O
H
N
O
H
NH2R
N
Br
Br
OH
N
Br
H
Br
Br
O
R-NH2
N
NHR
phenol
phenol,
HBr
Sheme 1. As a reaction medium, phenol reduces reaction time and temperature of halogen-replacement reactions, by
acting as proton donor, solvating agent, and source of phenoxide ion.
The novel dipyridines (3 and 4) were prepared from commercially available pentane-1,5-
diamine and bis-2-(aminoethyl)ether, and following the same synthetic protocol previously
reported [11].
Cyclophanes were obtained by cyclization of dipyridines 1-4 and the dibromide derivatives
in acetonitrile, according to our reported procedures [11]. The reaction was carried out by
adding 4 mM solution of the dibromide drop by drop to the dipyridine in acetonitrile at the
reflux temperature of the mixture for a period of 10–12 days, which favors the cyclization step
and avoids the intermolecular reaction [17]. In order to shorten the reaction time, microwave
was used. Thus, dipyridine and dibromide derivatives in acetonitrile were microwave-
irradiated at 140 ºC for 20 min. Under these conditions, similar yields were obtained as
compared to standard heating at the boiling point of the solvent (acetonitrile). Similarly bis-
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2Br
HN NH
N N
Linker 2
Linker 1
Compound Linker 1 Linker 2
VGP-222 (CH2)5
VGP-234 (CH2)2 O (CH2)2
VGP-310 (CH2)5
VGP-312 (CH2)2 O (CH2)2
VGP-318 (CH2)5 (CH2)5
VGP-328 (CH2)2 O (CH2)2
VGP-334 (CH2)5 (CH2)2 O (CH2)2
VGP-340 (CH2)2 O (CH2)2 (CH2)2 O (CH2)2
VGP-352 (CH2)2 O (CH2)2 (CH2)5
Table 4. Structures of the symmetrical bis-pyridinium diazacyclophanes.
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quinolinium cyclophanes [18–20] needed to be purified by tedious reverse-phase preparative
HPLC because conventional purification methods failed to give analytically pure samples for
biological testing, despite having been obtained under high-dilution conditions (1–2 mM). In
our case, this represents a great advantage for the accessibility of such an interesting class of
compounds (Scheme 2).
2Br
HN NH
N N
Linker 2
Linker 1
B
H2N Linker 2 NH2 + 2
N
Br
Phenol
HN NH
N N
Linker 2
Br Br
Linker 1
CH3CN
Linker 2 =
=
Linker 2 =
=
1 [8]
2 [8]
= (CH2)5 = (CH2)5 3 (61%)
= (CH2)2 O (CH2)2 = (CH2)2 O (CH2)2 4 (61%)
= (CH2)5
= (CH2)2 O (CH2)2
Linker 1
=
VGP-222 (34%)
VGP-234 (28%)
VGP-310 (58%)
VGP-312 (50%)
VGP-318 (33%)
VGP-328 (69%)
VGP-334 (21%)
VGP-340 (35%)
VGP-352 (33%)
Sheme 2. General synthesis of the symmetrical bis-pyridinium diazacyclophanes.
3.1. Anti-leishmanial activity
The final nine cyclophanes were tested as anti-leishmanial agents against promastigotes and
intracellular amastigotes of L. donovani and L. major [15]. The results are shown in Table 5,
where miltefosine and AmB were used as reference drugs.
All assayed compounds exhibit activity against promastigotes and intracellular amastigotes
of L. major and L. donovani, being more active in L. major, with EC50 values lying in the range 1
and 17 μM in amastigotes. Compounds VGP-310, VGP-318, VGP-334, VGP-340, and VGP-352
display EC50 values below 1 μM against promastigotes of L. major, an activity 100-fold higher
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than that obtained in promastigotes of L. donovani. However, the differences in activity
decrease in the amastigote forms, because some of these compounds are less active in amas‐
tigotes than in promastigotes of L. major and more active in amastigotes than in promastigotes
of L. donovani.
EC50 promastigotes (µM) EC50 amastigotes (µM) [SI]b
THP-1 toxicity EC50
(µM)
Compound L. major L. donovani L. major L. donovani
VGP-222 16.84 ± 1.20 51.97 ± 1.97 5.94 ± 0.93 [32.3] 13.53 ± 1.40 [14.2] 191.90 ± 8.12
VGP-234 5.97 ± 0.35 33.77 ± 4.68 8.67 ± 1.04 [22.5] 8.92 ± 1.96 [10.3] 195.17 ± 6.41
VGP-310 0.17 ± 0.01 26.41± 1.28 0.97 ± 0.27 [170.2] 38.33 ± 1.74 [4.3] 165.06 ± 21.29
VGP-312 26.48 ± 2.44 76.87 ± 9.59 17.15 ± 1.50 [12.9] 63.67 ± 5.21 [3.5] 221.89 ± 8.27
VGP-318 0.07 ± 0.01 10.64 ± 1.03 1.26 ± 0.30 [122.3] 7.62 ± 0.16 [20.2] 154.07 ± 5.95
VGP-328 2.87 ± 0.36 76.27 ± 4.96 1.61 ± 0.35 [120.8] 21.25 ± 2.03 [9.2] 194.41 ± 2.95
VGP-334 0.26 ± 0.02 31.47 ± 2.53 2.59 ± 0.23 [62.7] 33.19 ± 0.57 [4.9] 162.44 ± 6.07
VGP-340 0.19 ± 0.01 23.43 ± 0.57 2.24 ± 0.35 [57.2] 20.72 ± 1.07 [6.2] 128.22 ± 9.78
VGP-352 0.26 ± 0.01 31.41 ± 3.02 2.18 ± 0.05 [98.5] 12.95 ± 1.86 [16.6] 214.65 ± 13.80
AmB 0.32 ± 0.02 0.21 ± 0.01 0.24 ± 0.01 [59.7] 0.28 ± 0.13 [51.1] 14.32 ± 4.10
Miltefosine 16.65 ± 1.23 6.60 ± 1.57 10.61 ± 0.89 [2.5] 0.88 ± 0.14 [30.5] 26.86 ± 3.08
aParasites were grown for 72 h at 28 °C (promastigotes) or 37 ºC (intracellular amastigotes) in the presence of increasing
concentrations of compounds. THP-1 cells were grown for 72 h at 37 ºC, in the presence of increasing concentrations of
compounds. Promastigote and THP-1 viability was determined using an MTT-based assay. Number of intracellular
amastigotes was determined by nuclear staining. AmB, and miltefosine were used as standard anti-leishmanial agents.
Data are means ± SD of three independent determinations.
bSelectivity indexes [SI] were calculated by dividing the EC50 THP-1 by that for intracellular amastigotes. Compound
VGP-318 (grey color) was selected for further studies of the mechanism of action.
Table 5. Anti-leishmanial activity and toxicity in THP-1 cells of symmetrical bis-pyridinium diazacyclophanesa.
In general, from a structural point of view, compounds with two aliphatic linkers show better
activity against promastigotes of L. major than compounds with an aromatic linker. However,
the presence of an aromatic spacer increases the activity in intracellular amastigotes relative
to the activity in promastigotes, except for VGP-310. This could be due to the higher lipophi‐
licity of these structures that allowed a better penetration into THP-1 cells. Nevertheless, most
compounds displayed higher activity in intracellular amastigotes than in promastigotes of L.
donovani. Regarding the aliphatic linker, the presence of an oxygen atom in the linker did not
involve significant differences in the activity. All diazacyclophanes exhibited very low toxicity
against THP-1 cells (EC50 values between 128 and 220 μM) and some of them evince a higher
selectivity index than the reference compounds.
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Compound VGP-318 was chosen as a representative compound to further investigate the
mechanism of action of this new family of compounds [15]. This compound shows promising
activity against intracellular amastigotes of L. major (EC50 1.3 ± 0.3 μM), with a selectivity index
(122) higher than those of AmB (51) and miltefosine (30). It is also the most active diazacyclo‐
phane derivative against intracellular amastigotes of L. donovani (EC50 7.6 ± 0.2 μM).
3.2. Drug susceptibility assay of L. donovani lines overexpressing CEK or EK
As we have previously published that other bis-pyridinium diazacyclophanes were ChoK
inhibitors and active anti-proliferative drugs [11], we performed a sensitivity test for VGP-318
in promastigotes and intracellular amastigotes of L. donovani overexpressing the Leishmania
enzymes CEK or EK. The sensitivity for VGP-318 is similar in both promastigotes and
intracellular amastigotes overexpressing CEK and EK versus control parasites (Table 6). This
result suggests that the anti-leishmanial activity of these compounds is not related to the CEK
and EK enzymes [15].
EC50 (μM)
Plasmid Promastigotes Amastigotes
pXG 13.50 ± 0.32 8.84 ± 0.18
pXG-CEK 11.51 ± 0.52 12.70 ± 2.03
pXG-EK 12.04 ± 0.42 10.54 ± 1.42
aControl (pXG) and transfected (pXG-CEK and pXG-EK) parasites were grown for 72 h at 28 °C (promastigotes) or 37 ºC
(intracellular amastigotes) in the presence of increasing concentrations of compound. Data are means ± SD of three
independent determinations.
Table 6. Susceptibility to VGP-318 of L. donovani lines overexpressing CEK or EK.a
3.3. Effect of VGP-318 on Leishmania metabolism
In order to investigate the anti-leishmanial mechanism of action of compound VGP-318, we
focused the studies on the energetic metabolism of Leishmania promastigotes [15]. First, the
effect of the compound on intracellular ATP levels was analyzed by the bioluminescence assay,
which generates a luminescent signal proportional to the amount of ATP. In L. major, this assay
showed a rapid decrease in the intracellular ATP levels which depends on the compound
concentration (Figure 4A). However, no effect was observed on L. donovani after incubation
with 30 μM for 3 h (Figure 4B). The decrease in the ATP levels may be caused mainly by an
effect on the ATP synthesis or a release of the intracellular ATP due to the permeabilization of
plasma membrane. However, under conditions that decrease 95% of the ATP relative to control
(30 μM for 3 h), no sign of plasma membrane alteration was observed (Figure 5), showing that
the drop of free intracellular ATP is not due to disruption of the plasma membrane and
suggesting that this may be due to a defect in the ATP synthesis.
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Figure 4. Effect of VGP-318 on ATP levels in Leishmania promastigotes. Changes in intracellular ATP levels in L. major
(A) or L. Donovani (B) promastigotes treated with 0.2 (black bar) or 30 μM (white bar) of compound VGP-318 were
determined using the bioluminescence assay. Data are means ± SD of three independent experiments. Significant dif‐
ferences were determined using Student's t-test (*p<0.01).
Figure 5. Compound VGP-318 does not alter the plasma membrane potential in Leishmania lines. Promastigotes were
incubated with 30 μM of compound VGP-318 for 3 h and then treated with 2 μM of the specific plasma membrane
potential probe DIBAC4(3) for 10 min at 28 ºC. Untreated parasites were used as control, and treatment with 10 μM
CCCP was used as 100% depolarization of the plasma membrane potential. Data are means ± SD of three independent
experiments. Significant differences were determined using Student's t-test (*p< 0.01).
In Leishmania, the ATP is mainly synthesized by mitochondrial oxidative phosphorylation [21].
The anti-parasitic activity of many drugs, such as pentamidine and miltefosine, is mediated
by an alteration of the mitochondrial membrane potential (∆Ψm) [22, 23]. To determine whether
the intracellular ATP decay was associated with an effect of VGP-318 on the mitochondria, the
variation of its electrochemical potential was monitored in parasites incubated with VGP-318
using the JC-1 fluorescent marker. L. major parasites incubated for 1 h with 0.2 μM of VGP-318
(conditions where there was 50% decay in the ATP levels) showed a significant decrease in
JC-1 ratio compared with untreated parasites (Figure 6), evidencing a depolarization of the
mitochondrial potential. However, in L. donovani promastigotes non-significant depolarization
was observed after treatment with 30 μM of VGP-318 for 3 h (Figure 6). The depolarization of
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the ∆Ψm in L. major promastigotes suggests that this compound may cause damage in the
mitochondria, leading to a fall in the intracellular ATP levels and the death of parasites.
Figure 6. Effect of VGP-318 on the ∆Ψm of Leishmania promastigotes. Promastigotes were treated with 0.2 μM (L. major)
or 30 μM (L. donovani) of compound VGP-318 for 3 h and then incubated with 5 μM JC-1 for 10 min for the ∆Ψm deter‐
mination. The FL2/FL1 fluorescence ratio was measured by flow cytometry analysis. Untreated parasites were used as
control, and treatment with 10 μM FCCP for 10 min was used as full depolarization controls. Data are means ± SD of
three independent experiments. Significant differences were determined using Student's t-test (*p<0.01).
The lack of effect of compound VGP-318 in L. donovani may be explained by the lower activity
of this compound; VGP-318 is 100-fold less active in promastigote forms of L. donovani than
in L. major. Additionally, VGP-318 induces a slight depolarization of the ∆Ψm in L. Donovani
promastigotes, suggesting that a longer incubation time is necessary to produce significant
mitochondrial damage leading to failure of ATP synthesis. Compound VGP-318 has been
highlighted very recently [24].
4. Conclusions
In the search of new drugs against leishmaniasis, we have synthesized and evaluated two set
of symmetrical bis-pyridinium derivatives: (i) bis-pyridinium and bis-quinolinium acyclic
structures which contain a linker and 4-substituted cyclic or acyclic amino groups in the two
cationic heads and (ii) bis-pyridinium diazacyclophanes that are rigid derivatives with an
upper spacer which joins the two exocyclic amino groups and a lower spacer joining the two
positively charged nitrogen atoms. Restriction of conformational flexibility could be an
important consideration for the design of anti-leishmanial agents. Global constraint was
obtained by backbone cyclization in a tail-to-tail fashion. This popular tactic in medicinal
chemistry remains in some extent empirical, but has met successes, mainly for the elaboration
of working or preliminary pharmacophores.
All these bis-pyridinium salts show activity against promastigotes and intracellular amasti‐
gotes of the protozoan parasites L. donovani and L. major [14, 15]. Most acyclic compounds show
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a similar behavior in both species, being slightly more active against L. major amastigotes. All
the cyclophanes are more active against promastigotes and amastigotes of L. major than L.
donovani, although with a lower potency than the acyclic derivatives. However, in contrast to
the variable toxicity of the acyclic compounds [14], all cyclophanes exhibit very low toxicity
against mammalian cells THP-1 and some of them evince a higher safety margin than well-
known anti-leishmanial drugs such as AmB and miltefosine [15].
Although we have studied certain aspects of the mechanism of action of these compounds [14,
15], it has not been determined any key target on which they are operating, which would be
decisive for the rational design of new structures. Future work should be directed to carry out
studies to elucidate the metabolism, pharmacokinetics, and mechanism of action of these
compounds. On the other hand, it would be interesting to conduct a screening of a large
number of symmetrical bis-pyridinium compounds that allows us to study structure–activity
relationships. In any case, additional experiments are necessary for evaluating the toxicity and
potency of these compounds by in vivo assays.
Note
Some parts of this chapter have been previously published in references [14, 15].
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